.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Boehringer Ingelheim
Chinese Patent Office
Baxter
Healthtrust
Daiichi Sankyo
Johnson and Johnson
Citi
Queensland Health

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 076122

« Back to Dashboard
NDA 076122 describes MIRTAZAPINE, which is a drug marketed by Impax Labs Inc, Actavis Labs Fl Inc, Actavis Elizabeth, Watson Labs, Teva, Upsher-smith Labs, Aurobindo, Mylan, Sun Pharm Inds Inc, Ivax Sub Teva Pharms, Apotex Inc, Roxane, Aurobindo Pharma Ltd, Mylan Pharms Inc, and Zydus Pharms Usa Inc, and is included in twenty NDAs. It is available from forty-four suppliers. Additional details are available on the MIRTAZAPINE profile page.

The generic ingredient in MIRTAZAPINE is mirtazapine. There are eighteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the mirtazapine profile page.

Summary for NDA: 076122

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 076122

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MIRTAZAPINE
mirtazapine
TABLET;ORAL 076122 ANDA Mylan Pharmaceuticals Inc. 0378-3515 0378-3515-01 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-3515-01)
MIRTAZAPINE
mirtazapine
TABLET;ORAL 076122 ANDA Mylan Pharmaceuticals Inc. 0378-3515 0378-3515-10 1000 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-3515-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength15MG
Approval Date:Jun 19, 2003TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Jun 19, 2003TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength45MG
Approval Date:Jun 19, 2003TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Dow
Covington
Federal Trade Commission
McKesson
Teva
Baxter
US Army
McKinsey
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot